IN2012DN02737A - - Google Patents

Download PDF

Info

Publication number: IN2012DN02737A
Authority: IN; India
Prior art keywords: minding; multispecific; diagnosis; proteins; disease
Prior art date: 2009-09-01

Application number

Other languages

English (en)

Inventor

Tariq Ghayur

Junjian Liu

Sharmila Manoj

Susan E Brophy

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-09-01

Filing date

2010-09-01

Publication date

2015-09-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN02737(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-09-01 Application filed by Abbott Lab filed Critical Abbott Lab

2015-09-11 Publication of IN2012DN02737A publication Critical patent/IN2012DN02737A/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Tropical Medicine & Parasitology (AREA)

IN2737DEN2012 2009-09-01 2010-09-01 IN2012DN02737A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US23890809P	2009-09-01	2009-09-01
US25194609P	2009-10-15	2009-10-15
PCT/US2010/047543 WO2011028811A2 (fr)	2009-09-01	2010-09-01	Immunoglobulines à double domaine variable et leurs utilisations

Publications (1)

Publication Number	Publication Date
IN2012DN02737A true IN2012DN02737A (fr)	2015-09-11

Family

ID=43649948

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN2737DEN2012 IN2012DN02737A (fr)	2009-09-01	2010-09-01

Country Status (26)

Country	Link
US (2)	US8586714B2 (fr)
EP (1)	EP2473524A4 (fr)
JP (1)	JP2013503607A (fr)
KR (1)	KR20120060877A (fr)
CN (1)	CN102612524A (fr)
AR (1)	AR078254A1 (fr)
AU (1)	AU2010289527C1 (fr)
BR (1)	BR112012004710A2 (fr)
CA (1)	CA2772628A1 (fr)
CL (1)	CL2012000559A1 (fr)
CO (1)	CO6511254A2 (fr)
CR (1)	CR20120154A (fr)
DO (1)	DOP2012000055A (fr)
EC (1)	ECSP12011730A (fr)
GT (1)	GT201200058A (fr)
IL (1)	IL218402A0 (fr)
IN (1)	IN2012DN02737A (fr)
MX (1)	MX2012002651A (fr)
NZ (1)	NZ598929A (fr)
PE (1)	PE20121530A1 (fr)
RU (1)	RU2012112550A (fr)
SG (1)	SG178602A1 (fr)
TW (1)	TW201119673A (fr)
UY (1)	UY32870A (fr)
WO (1)	WO2011028811A2 (fr)
ZA (1)	ZA201202268B (fr)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (fr) *	2008-04-29	2012-04-25	Abbott Lab	Immunoglobulines à double domaine variable et utilisations
KR20110016959A (ko) *	2008-06-03	2011-02-18	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
EP2297209A4 (fr) *	2008-06-03	2012-08-01	Abbott Lab	Immunoglobulines à deux domaines variables et leurs utilisations
US8822645B2 (en) *	2008-07-08	2014-09-02	Abbvie Inc.	Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
TW201109438A (en) *	2009-07-29	2011-03-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
CA2771575A1 (fr)	2009-08-29	2011-03-03	Abbott Laboratories	Proteines therapeutiques se liant a dll4
MX2012002651A (es) *	2009-09-01	2012-05-22	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR078651A1 (es) *	2009-10-15	2011-11-23	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3485908B1 (fr)	2009-10-16	2021-08-18	Mereo BioPharma 5, Inc.	Combinaison thérapeutique et utilisation d'anticorps antagonistes de dll4 et d'agents anti-hypertenseurs
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011109298A2 (fr)	2010-03-02	2011-09-09	Abbott Laboratories	Protéines thérapeutiques de liaison à dll4
UY33492A (es) *	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130100118A (ko)	2010-08-03	2013-09-09	아비에 인코포레이티드	이원 가변 도메인 면역글로불린 및 이의 용도
US9046513B2 (en)	2010-08-26	2015-06-02	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
UY33707A (es) *	2010-11-04	2012-05-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3252076B1 (fr)	2011-01-14	2019-09-04	The Regents Of The University Of California	Utilisation diagnostique d' anticorps thérapeutiques contre la protéine ror-1
MX336197B (es) *	2011-04-19	2016-01-11	Merrimack Pharmaceuticals Inc	Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
TWI583699B (zh)	2011-09-23	2017-05-21	安可美德藥物股份有限公司	Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
TW201333039A (zh) *	2011-12-30	2013-08-16	Abbvie Inc	雙可變域免疫球蛋白及其用途
AR089529A1 (es)	2011-12-30	2014-08-27	Abbvie Inc	Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
RU2691698C2 (ru)	2012-02-24	2019-06-17	ЭББВИ СТЕМСЕНТРКС ЭлЭлСи	Антитела против sez6 и способы их применения
US20140004131A1 (en)	2012-05-04	2014-01-02	Novartis Ag	Antibody formulation
HK1212448A1 (en)	2012-09-07	2016-06-10	The Governors Of The University Of Alberta	Methods and compositions for diagnosis of inflammatory liver disease
DK2839860T3 (da)	2012-10-12	2019-06-17	Medimmune Ltd	Pyrrolobenzodiazepiner og konjugater deraf
PT2906253T (pt)	2012-10-12	2018-11-05	Medimmune Ltd	Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
KR101995620B1 (ko)	2012-10-12	2019-07-03	에이디씨 테라퓨틱스 에스에이	피롤로벤조디아제핀-항체 컨주게이트
DK2906298T3 (en) *	2012-10-12	2018-12-17	Adc Therapeutics Sa	Pyrrolobenzodiazepine-antibody conjugates
BR112015008238A2 (pt)	2012-10-12	2017-11-28	Adc Therapeutics Sarl	conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
US9217042B2 (en) *	2012-10-23	2015-12-22	Abbott Cardiovascular Systems Inc.	Method of reducing MACE in diabetic patients subsequent to stent placement
CA2889638A1 (fr)	2012-10-31	2014-05-08	Oncomed Pharmaceuticals, Inc.	Methodes et surveillance d'un traitement par un antagoniste de dll4
PE20151179A1 (es)	2012-11-01	2015-09-12	Abbvie Inc	Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
US20170275367A1 (en)	2012-11-21	2017-09-28	Janssen Biotech, Inc.	Bispecific EGFR/C-Met Antibodies
KR102373193B1 (ko)	2012-11-21	2022-03-10	얀센 바이오테크 인코포레이티드	이중특이성 EGFR/c-Met 항체
LT2953975T (lt) *	2013-02-05	2017-12-27	Sanofi	Imunovizualizuojantis agentas, skirtas naudoti terapijai su antikūno-vaisto konjugatu
JP2016515093A (ja)	2013-02-05	2016-05-26	サノフイ	抗体−薬物コンジュゲート療法とともに使用するための免疫イメージング剤
US9989524B2 (en)	2013-02-05	2018-06-05	Sanofi	Immuno imaging agent for use with antibody-drug conjugate therapy
SI2953977T1 (en) *	2013-02-05	2018-02-28	Sanofi	An immuno-contrast agent for use in antibody-drug conjugate therapy
HK1219044A1 (zh) *	2013-03-15	2017-03-24	艾伯维德国有限责任两合公司	抗egfr抗体药物偶联物制剂
AU2014227732A1 (en)	2013-03-15	2015-09-17	Abbvie Inc.	Dual specific binding proteins directed against IL-1 beta and IL-17
BR112015025549A2 (pt)	2013-04-07	2017-10-10	Bioex Therapeutics Inc	anticorpo contra o receptor do fator de crescimento epidérmico
JP6693872B2 (ja)	2013-07-25	2020-05-13	シトムクスセラピューティクス，インコーポレイティド	多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
EP3049442A4 (fr)	2013-09-26	2017-06-28	Costim Pharmaceuticals Inc.	Méthodes de traitement de cancers hématologiques
US10010624B2 (en)	2013-10-11	2018-07-03	Medimmune Limited	Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (fr)	2013-10-11	2015-04-16	Spirogen Sàrl	Conjugués anticorps-pyrrolobenzodiazépine
UA122479C2 (uk)	2014-01-24	2020-11-25	Дана-Фарбер Кенсер Інстітьют, Інк.	Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl)	2014-01-31	2019-10-31	Novartis Ag	Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
PL3104853T3 (pl)	2014-02-10	2020-05-18	Respivant Sciences Gmbh	Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
JP2017505348A (ja)	2014-02-10	2017-02-16	パタラファーマリミテッドライアビリティカンパニー	肺疾患治療のための肥満細胞安定剤
EA201691765A1 (ru)	2014-03-14	2016-12-30	Новартис Аг	Молекулы антител против lag-3 и их применения
MX2016017393A (es)	2014-07-01	2017-09-05	Pfizer	Diacuerpos heterodimericos biespecificos y sus usos.
WO2016014725A1 (fr)	2014-07-22	2016-01-28	The University Of Notre Dame Du Lac	Constructions moléculaires et utilisations correspondantes
CA2955947A1 (fr)	2014-07-25	2016-01-28	Cytomx Therapeutics, Inc.	Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispecifiques, anticorps anti-cd3 activables multispecifiques et procedes d'utilisation de ces anticorps
GB201416112D0 (en)	2014-09-12	2014-10-29	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
EP3191126B1 (fr)	2014-09-13	2020-05-13	Novartis AG	Thérapies combinées d'inhibiteurs d'alk
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3212233B1 (fr)	2014-10-31	2020-06-24	Oncomed Pharmaceuticals, Inc.	Thérapie combinée pour le traitement d'une maladie
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
US10717783B2 (en) *	2014-12-22	2020-07-21	Zeren Gao	Bispecific tetravalent antibodies and methods of making and using thereof
WO2016154585A1 (fr) *	2015-03-26	2016-09-29	Charles Sentman	Fragments de liaison à l'antigène anti-mica, molécules hybrides, cellules exprimant ceux-ci et procédés d'utilisation
GB201506411D0 (en)	2015-04-15	2015-05-27	Bergenbio As	Humanized anti-axl antibodies
GB201506402D0 (en)	2015-04-15	2015-05-27	Berkel Patricius H C Van And Howard Philip W	Site-specific antibody-drug conjugates
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US10722580B2 (en) *	2015-05-13	2020-07-28	University Of Washington	Compositions and methods for treatment and prevention of uropathogenic E. coli infection
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US20180340025A1 (en)	2015-07-29	2018-11-29	Novartis Ag	Combination therapies comprising antibody molecules to lag-3
US10265296B2 (en)	2015-08-07	2019-04-23	Respivant Sciences Gmbh	Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (fr)	2015-08-07	2017-02-16	Patara Pharma, LLC	Méthodes de traitement de troubles liés aux mastocytes par des stabilisateurs de mastocytes
US11339213B2 (en)	2015-09-23	2022-05-24	Mereo Biopharma 5, Inc.	Methods and compositions for treatment of cancer
CN108495651A (zh)	2015-12-17	2018-09-04	诺华股份有限公司	抗pd-1的抗体分子及其用途
GB201601431D0 (en)	2016-01-26	2016-03-09	Medimmune Ltd	Pyrrolobenzodiazepines
GB201602359D0 (en)	2016-02-10	2016-03-23	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en)	2016-02-10	2016-03-23	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
MY199595A (en)	2016-03-02	2023-11-08	Eisai R&D Man Co Ltd	Eribulin-based antibody-drug conjugates and methods of use
GB201607478D0 (en)	2016-04-29	2016-06-15	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
JP2019528320A (ja)	2016-08-31	2019-10-10	レシュピファントサイエンシスゲゼルシャフトミットベシュレンクターハフトゥングＲｅｓｐｉｖａｎｔＳｃｉｅｎｃｅｓＧｍｂｈ	特発性肺線維症による慢性咳の治療のためのクロモリン組成物
EP3522983A4 (fr)	2016-10-07	2020-06-03	Respivant Sciences GmbH	Compositions à base de cromolyne pour le traitement d'une fibrose pulmonaire
GB201617466D0 (en)	2016-10-14	2016-11-30	Medimmune Ltd	Pyrrolobenzodiazepine conjugates
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
RS61795B1 (sr)	2017-02-08	2021-06-30	Adc Therapeutics Sa	Konjugati pirolobenzodiazepin antitela
GB201702031D0 (en)	2017-02-08	2017-03-22	Medlmmune Ltd	Pyrrolobenzodiazepine-antibody conjugates
BR102018006205A2 (pt)	2017-03-28	2021-03-23	Cell Design Labs, Inc.	Polipeptídeos quiméricos e métodos de alterar a localização da membrana dos mesmos
SMT202200490T1 (it)	2017-04-18	2023-01-13	Medimmune Ltd	Coniugati di pirrolobenzodiazepina
WO2018193102A1 (fr)	2017-04-20	2018-10-25	Adc Therapeutics Sa	Polythérapie avec un conjugué anticorps anti-axl-médicament
KR102442736B1 (ko)	2017-06-14	2022-09-16	에이디씨 테라퓨틱스 에스에이	항-cd19 adc의 투여를 위한 투약량 체제
US11325957B2 (en)	2017-06-19	2022-05-10	Cell Design Labs, Inc.	Methods and compositions for reducing the immunogenicity of chimeric notch receptors
SI3668874T1 (sl)	2017-08-18	2022-04-29	Medimmune Limited	Pirolobenzodiazepinski konjugati
CA3086045A1 (fr)	2017-12-19	2019-06-27	Akouos, Inc.	Administration d'anticorps therapeutiques mediee par aav a l'oreille interne
WO2019126358A1 (fr)	2017-12-22	2019-06-27	Cell Design Labs, Inc.	Récepteurs antigéniques chimériques à chaîne unique et à chaînes multiples
US12247060B2 (en)	2018-01-09	2025-03-11	Marengo Therapeutics, Inc.	Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3755712A1 (fr)	2018-02-21	2020-12-30	Cell Design Labs, Inc.	Récepteurs transmembranaires chimériques et leurs utilisations
GB201803342D0 (en)	2018-03-01	2018-04-18	Medimmune Ltd	Methods
EP3765517A1 (fr)	2018-03-14	2021-01-20	Elstar Therapeutics, Inc.	Molécules multifonctionnelles se liant à calréticuline et utilisations associees
GB201806022D0 (en)	2018-04-12	2018-05-30	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
WO2020010250A2 (fr)	2018-07-03	2020-01-09	Elstar Therapeutics, Inc.	Molécules d'anticorps anti-tcr et leurs utilisations
US20200041518A1 (en)	2018-08-03	2020-02-06	CellMax Life, Inc.	Lipid vesicle-coated magnetic beads and uses of the same
CN112996805A (zh)	2018-08-30	2021-06-18	Hcw生物科技公司	多链嵌合多肽和其用途
WO2020047333A1 (fr)	2018-08-30	2020-03-05	HCW Biologics, Inc.	Polypeptides chimériques à chaîne unique et leurs utilisations
CA3109139A1 (fr)	2018-08-30	2020-03-05	HCW Biologics, Inc.	Methodes de traitement de troubles lies au vieillissement
CA3118692A1 (fr) *	2018-11-06	2020-05-14	Alsatech, Inc.	Therapie genique de maladies neurodegeneratives a base de cellules
AU2020226893B2 (en)	2019-02-21	2025-02-27	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7579795B2 (ja)	2019-02-21	2024-11-08	マレンゴ・セラピューティクス，インコーポレーテッド	ＮＫｐ３０に結合する抗体分子およびその使用
CN113631560B (zh)	2019-03-15	2025-02-18	麦迪穆有限责任公司	氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
WO2020216847A1 (fr)	2019-04-23	2020-10-29	Sanofi	Formulations d'anticorps stables et à faible viscosité et leurs utilisations
CN113811546B (zh) *	2019-05-07	2025-03-11	免疫里森公司	前体三特异性抗体构建体及其使用方法
JP7137696B2 (ja)	2019-05-14	2022-09-14	プロヴェンション・バイオ・インコーポレイテッド	１型糖尿病を予防するための方法および組成物
EP3980130A1 (fr)	2019-06-06	2022-04-13	Mythic Therapeutics, Inc.	Constructions de protéine de liaison à l'antigène et utilisations de celles-ci
CN114786732A (zh)	2019-06-06	2022-07-22	神话治疗股份有限公司	抗原结合蛋白构建体及其用途
EP3980129A1 (fr)	2019-06-07	2022-04-13	Mythic Therapeutics, Inc.	Constructions de protéines de liaison à l'antigène et utilisations associées
AU2020294797B2 (en)	2019-06-21	2025-12-18	Immunitybio, Inc.	Multi-chain chimeric polypeptides and uses thereof
US20220306751A1 (en)	2019-09-13	2022-09-29	Mythic Therapeutics, Inc.	Antigen-binding protein constructs and uses thereof
JP7818509B2 (ja)	2019-10-04	2026-02-20	ミシクセラピューティクス，インコーポレイテッド	抗原結合タンパク質構築物およびその使用
WO2021138474A2 (fr)	2020-01-03	2021-07-08	Marengo Therapeutics, Inc.	Molécules d'anticorps anti-tcr et leurs utilisations
WO2021141996A1 (fr)	2020-01-06	2021-07-15	Cytomx Therapeutics, Inc.	Polypeptides à chaîne unique et à chaînes multiples qui se lient de manière spécifique à cd3 epsilon
CA3169243A1 (fr)	2020-02-11	2021-08-19	HCW Biologics, Inc.	Methodes d'activation de lymphocytes t regulateurs
CN116670163A (zh)	2020-02-11	2023-08-29	Hcw生物科技公司	治疗年龄相关疾病和炎性疾病的方法
WO2021163299A1 (fr)	2020-02-11	2021-08-19	HCW Biologics, Inc.	Résine de chromatographie et utilisations associées
WO2021195362A1 (fr)	2020-03-26	2021-09-30	Seagen Inc.	Méthodes de traitement du myélome multiple
AU2021262794B2 (en)	2020-04-29	2026-06-18	Immunitybio, Inc.	Anti-CD26 proteins and uses thereof
WO2021247003A1 (fr)	2020-06-01	2021-12-09	HCW Biologics, Inc.	Méthodes de traitement de troubles liés au vieillissement
IL298608A (en)	2020-06-01	2023-01-01	Hcw Biologics Inc	Methods for treating disorders related to aging
US12024545B2 (en)	2020-06-01	2024-07-02	HCW Biologics, Inc.	Methods of treating aging-related disorders
KR20230092863A (ko)	2020-06-11	2023-06-26	프로벤션 바이오, 인코포레이티드	제1형 당뇨병을 예방하기 위한 방법 및 조성물
CA3195512A1 (fr)	2020-10-14	2022-04-21	Vahe Bedian	Compositions et procedes pour le traitement d'une maladie oculaire thyroidienne
IL303317A (en)	2020-12-01	2023-07-01	Akouos Inc	ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
CN117529499A (zh)	2021-02-03	2024-02-06	神话治疗股份有限公司	抗met抗体和其用途
JP2024510435A (ja)	2021-03-18	2024-03-07	シージェンインコーポレイテッド	生体活性化合物の内部移行複合体からの選択的薬物放出
AU2022254042A1 (en)	2021-04-07	2023-09-14	Mythic Therapeutics, Inc.	Antigen-binding protein constructs and antibodies and uses thereof
MX2023013851A (es)	2021-05-24	2023-12-08	Provention Bio Inc	Metodos para el tratamiento de diabetes tipo 1.
JP2024531151A (ja)	2021-08-10	2024-08-29	ビリジアンセラピューティクス，インコーポレイテッド	甲状腺眼疾患の処置のための組成物、用量および方法
JP7892764B2 (ja)	2021-08-11	2026-07-21	イミュニティーバイオインコーポレイテッド	多重鎖キメラポリペプチド及び肝疾患の治療におけるその使用
TW202327650A (zh)	2021-09-23	2023-07-16	美商思進公司	治療多發性骨髓瘤之方法
JP7767613B2 (ja)	2021-11-15	2025-11-11	システィミューン，インコーポレイテッド	二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用
CA3242661A1 (fr) *	2022-01-07	2023-07-13	Viridian Therapeutics, Inc.	Compositions et methodes pour le traitement d'une maladie oculaire thyroidienne
AR128422A1 (es)	2022-02-02	2024-05-08	Akouos Inc	Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
AU2023228683B2 (en)	2022-03-02	2025-12-04	Immunitybio, Inc.	Method of treating pancreatic cancer
EP4504782A2 (fr)	2022-04-01	2025-02-12	CytomX Therapeutics, Inc.	Protéines de liaison au cd3 et leurs procédés d'utilisation
US12594323B2 (en)	2022-04-13	2026-04-07	Immunitybio, Inc.	Methods of reducing neuroinflammation
EP4507712A1 (fr)	2022-04-13	2025-02-19	ImmunityBio, Inc.	Polypeptide chimérique à chaînes multiples destiné à être utilisé dans le traitement d'un trouble de gènes de l'horloge circardienne
US20260209386A1 (en)	2022-05-19	2026-07-23	Mythic Therapeutics, Inc.	Ptk7-binding proteins with ph-dependent binding and uses thereof
JP2025525868A (ja)	2022-08-01	2025-08-07	サイトムエックスセラピューティクス，インク．	プロテアーゼ切断性部分及びその使用方法
TW202424184A (zh)	2022-08-01	2024-06-16	美商Ｃｙｔｏｍｘ生物製藥公司	蛋白酶可切割部分及其使用方法
US20260015425A1 (en)	2022-08-01	2026-01-15	Cytomx Therapeutics, Inc.	Protease-cleavable substrates and methods of use thereof
AR130077A1 (es)	2022-08-01	2024-10-30	Cytomx Therapeutics Inc	Substratos escindibles por proteasas, y métodos de uso de los mismos
WO2024030845A1 (fr)	2022-08-01	2024-02-08	Cytomx Therapeutics, Inc.	Fractions clivables par protéase et procédés d'utilisation associés
CN120035607A (zh)	2022-10-12	2025-05-23	神话治疗股份有限公司	Lrrc-15结合蛋白构建体及其用途
EP4688865A2 (fr)	2023-03-29	2026-02-11	Mythic Therapeutics, Inc.	Protéines de liaison à trop2 et leurs utilisations
MX2025014738A (es) *	2023-06-09	2026-02-03	Antengene Biologics Ltd	Nuevos anticuerpos dirigidos a cd3 y otra diana y usos de los mismos
WO2024263932A2 (fr)	2023-06-23	2024-12-26	Mythic Therapeutics, Inc.	Protéines de liaison à itgb6 et leurs utilisations
US20250295801A1 (en)	2024-03-21	2025-09-25	Seagen Inc.	Cd25 antibodies, antibody drug conjugates, and uses thereof
TW202602935A (zh)	2024-04-01	2026-01-16	美商米西克治療公司	抗原結合蛋白構築體及其用途
US20260021192A1 (en)	2024-07-17	2026-01-22	Topaz Therapeutics, Inc.	Proteins having a covalent warhead
WO2026035650A2 (fr)	2024-08-05	2026-02-12	Cytomx Therapeutics, Inc.	Polypeptides clivables et leurs procédés d'utilisation
US20260132185A1 (en)	2024-08-19	2026-05-14	HCW Biologics, Inc.	Multi-chain chimeric polypeptides and uses thereof
WO2026112478A1 (fr)	2024-11-24	2026-05-28	Mythic Therapeutics, Inc.	Protéines de liaison à lrrc15, anticorps multispécifiques anti-lrrc15 et anti-antigène tumoral (taa), lieurs de conjugaison, et leurs procédés d'utilisation et de production
WO2026152120A2 (fr)	2025-01-13	2026-07-16	HCW Biologics, Inc.	Polypeptides chimériques et utilisations associées

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU22545A1 (es)	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
EP0092918B1 (fr) *	1982-04-22	1988-10-19	Imperial Chemical Industries Plc	Formulations à libération continue
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4753894A (en) *	1984-02-08	1988-06-28	Cetus Corporation	Monoclonal anti-human breast cancer antibodies
US4943533A (en) *	1984-03-01	1990-07-24	The Regents Of The University Of California	Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5128326A (en) *	1984-12-06	1992-07-07	Biomatrix, Inc.	Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US6492107B1 (en)	1986-11-20	2002-12-10	Stuart Kauffman	Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3587814T2 (de)	1985-03-30	1994-11-10	Marc Ballivet	Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US4980286A (en) *	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) *	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
US4699784A (en) *	1986-02-25	1987-10-13	Center For Molecular Medicine & Immunology	Tumoricidal methotrexate-antibody conjugate
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) *	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja)	1987-03-18	2000-10-23	エス・ビィ・２・インコーポレイテッド	変性抗体の、または変性抗体に関する改良
US5258498A (en) *	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
WO1989006692A1 (fr)	1988-01-12	1989-07-27	Genentech, Inc.	Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
DE68927933T2 (de)	1988-09-02	1997-08-14	Dyax Corp	Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
FI903489A7 (fi)	1988-11-11	1990-07-10	Medical Res Council	Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
CA2016841C (fr)	1989-05-16	1999-09-21	William D. Huse	Methode de production de polymeres ayant une activite choisie
EP0478627A4 (en)	1989-05-16	1992-08-19	William D. Huse	Co-expression of heteromeric receptors
CA2016842A1 (fr)	1989-05-16	1990-11-16	Richard A. Lerner	Methode pour puiser dans le repertoire immunologique
AU6430190A (en)	1989-10-10	1991-05-16	Pitman-Moore, Inc.	Sustained release composition for macromolecular proteins
CA2071867A1 (fr)	1989-11-06	1991-05-07	Edith Mathiowitz	Mode de fabrication de microspheres proteiniques
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en)	1990-01-11	1991-08-05	Molecular Affinities Corporation	Production of antibodies using gene libraries
US6075181A (en) *	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
EP1690935A3 (fr)	1990-01-12	2008-07-30	Abgenix, Inc.	Génération d'anticorps xenogéniques
US5427908A (en) *	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
AT396939B (de)	1990-05-29	1993-12-27	Alois Dipl Ing Dr Jungbauer	Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
ES2139598T3 (es)	1990-07-10	2000-02-16	Medical Res Council	Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
CA2090126C (fr)	1990-08-02	2002-10-22	John W. Schrader	Methodes de production de proteines dotees d'une fonction desiree
EP0544809B1 (fr)	1990-08-24	1998-12-16	Ixsys, Inc.	Procede de production par synthese d'oligonucleotides ayant des codons aleatoires
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5780279A (en) *	1990-12-03	1998-07-14	Genentech, Inc.	Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
IE914504A1 (en)	1990-12-20	1992-07-01	Ixsys	Optimization of binding proteins
DE69233697T2 (de)	1991-03-01	2008-01-24	Dyax Corp., Cambridge	Verfahren zur Entwicklung von bindenden Mikroproteinen
AU658396B2 (en)	1991-03-06	1995-04-13	Merck Patent Gesellschaft Mit Beschrankter Haftung	Humanized and chimeric monoclonal antibodies
PT100379B (pt)	1991-04-10	1999-01-29	Scripps Research Inst	Bibliotecas de receptores heterodimericos usando fagomideos
JPH06507404A (ja)	1991-05-01	1994-08-25	ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン	感染性の呼吸性疾患の治療方法
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4118120A1 (de)	1991-06-03	1992-12-10	Behringwerke Ag	Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
JPH07503124A (ja)	1991-06-14	1995-04-06	ゾーマ・コーポレーション	微生物によって生産される抗体断片とそれらの複合体
EP0590058B1 (fr)	1991-06-14	2003-11-26	Genentech, Inc.	ANTICORP HUMANISE specifique pour heregulin
DE4122599C2 (de)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
JP3540315B2 (ja)	1991-09-23	2004-07-07	メディカルリサーチカウンシル	キメラ抗体の製造−組合せアプローチ
DE69233528T2 (de)	1991-11-25	2006-03-16	Enzon, Inc.	Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1024191E (pt)	1991-12-02	2008-12-22	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993011794A1 (fr)	1991-12-13	1993-06-24	Xoma Corporation	Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en)	1992-03-12	1999-06-15	Alkermes Controlled Therapeutics, Inc.	Modulated release from biocompatible polymers
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
ES2301158T3 (es)	1992-07-24	2008-06-16	Amgen Fremont Inc.	Produccion de anticuerpos xenogenicos.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5934272A (en)	1993-01-29	1999-08-10	Aradigm Corporation	Device and method of creating aerosolized mist of respiratory drug
AU6132994A (en)	1993-02-02	1994-08-29	Scripps Research Institute, The	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO1995001997A1 (fr)	1993-07-09	1995-01-19	Smithkline Beecham Corporation	ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
WO1995009917A1 (fr)	1993-10-07	1995-04-13	The Regents Of The University Of California	Anticorps bispecifiques et tetravalents, obtenus par genie genetique
EP0659766A1 (fr)	1993-11-23	1995-06-28	Schering-Plough	Anticorps monoclonaux humains contre des cytokines humains et méthode de fabrication de tels anticorps
US5565352A (en)	1993-11-24	1996-10-15	Arch Development Corporation	Deubiquitinating enzyme: compositions and methods
JPH09506262A (ja)	1993-12-08	1997-06-24	ジェンザイム・コーポレイション	特異的抗体の製造方法
CA2178590A1 (fr) *	1993-12-10	1995-06-15	Joan D. Tyner	Reactifs et procedes de detection du methotrexate
GB9401182D0 (en)	1994-01-21	1994-03-16	Inst Of Cancer The Research	Antibodies to EGF receptor and their antitumour effect
ES2201097T3 (es)	1994-01-31	2004-03-16	Trustees Of Boston University	Bibliotecas de anticuerpos policlonales.
ZA95960B (en)	1994-03-14	1995-10-10	Genetics Inst	Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5516637A (en) *	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
AU3272695A (en) *	1994-08-12	1996-03-07	Immunomedics Inc.	Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
ATE252894T1 (de)	1995-01-05	2003-11-15	Univ Michigan	Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
GB9504344D0 (en) *	1995-03-03	1995-04-19	Unilever Plc	Antibody fragment production
US6130364A (en)	1995-03-29	2000-10-10	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) *	1995-03-29	2000-07-18	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) *	1995-04-14	2000-02-01	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
AU705616B2 (en) *	1995-04-21	1999-05-27	Cell Genesys, Inc.	Generation of large genomic DNA deletions
CA2219361C (fr)	1995-04-27	2012-02-28	Abgenix, Inc.	Anticorps humains derives d'une xenosouris immunisee
WO1996034096A1 (fr)	1995-04-28	1996-10-31	Abgenix, Inc.	Anticorps humains derives de xeno-souris immunisees
US7060808B1 (en) *	1995-06-07	2006-06-13	Imclone Systems Incorporated	Humanized anti-EGF receptor monoclonal antibody
CA2222231A1 (fr)	1995-06-07	1996-12-19	Imclone Systems Incorporated	Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
AU710347B2 (en)	1995-08-31	1999-09-16	Alkermes Controlled Therapeutics, Inc.	Composition for sustained release of an agent
US5989830A (en) *	1995-10-16	1999-11-23	Unilever Patent Holdings Bv	Bifunctional or bivalent antibody fragment analogue
US6331431B1 (en)	1995-11-28	2001-12-18	Ixsys, Inc.	Vacuum device and method for isolating periplasmic fraction from cells
ATE239041T1 (de) *	1996-02-09	2003-05-15	Basf Ag	Humane antikörper welche an humanen tnfalpha binden
US5985320A (en)	1996-03-04	1999-11-16	The Penn State Research Foundation	Materials and methods for enhancing cellular internalization
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
JPH11507843A (ja)	1996-03-28	1999-07-13	ザ・ジョンズ・ホプキンス・ユニバーシティー	タンパク質の可溶性二価および多価ヘテロ二量体類縁体
WO1997038102A1 (fr)	1996-04-04	1997-10-16	Unilever Plc	Proteine, polyvalente et a specificites multiples, de fixation sur un antigene
US5874064A (en)	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5985309A (en)	1996-05-24	1999-11-16	Massachusetts Institute Of Technology	Preparation of particles for inhalation
US5855913A (en)	1997-01-16	1999-01-05	Massachusetts Instite Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US6699658B1 (en)	1996-05-31	2004-03-02	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
US6986890B1 (en) *	1996-11-21	2006-01-17	Kyowa Hakko Kogyo Co., Ltd.	Anti-human VEGF receptor Flt-1 monoclonal antibody
EP1972194A1 (fr)	1996-12-03	2008-09-24	Amgen Fremont Inc.	Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
DE69732306T2 (de)	1997-01-16	2006-01-12	Massachusetts Institute Of Technology, Cambridge	Zubereitung von partikelhaltigen arzneimitteln zur inhalation
IL131016A (en)	1997-01-21	2004-12-15	Gen Hospital Corp	Selection of proteins using RNA-protein blends
US6057098A (en) *	1997-04-04	2000-05-02	Biosite Diagnostics, Inc.	Polyvalent display libraries
US6884879B1 (en) *	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
AU8691398A (en)	1997-08-04	1999-02-22	Ixsys, Incorporated	Methods for identifying ligand specific binding molecules
US5989463A (en)	1997-09-24	1999-11-23	Alkermes Controlled Therapeutics, Inc.	Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv)	1997-10-23	2000-04-17	Biogram Ab	Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
DK1027439T3 (da)	1997-10-27	2010-05-10	Bac Ip Bv	Multivalente antigenbindende proteiner
KR20010034554A (ko)	1998-03-03	2001-04-25	레이몬드, 엠. 위티	치료제로서의 ｃｄ147 결합 분자
US20020029391A1 (en)	1998-04-15	2002-03-07	Claude Geoffrey Davis	Epitope-driven human antibody production and gene expression profiling
JP4334141B2 (ja)	1998-04-20	2009-09-30	グリカートバイオテクノロジーアクチェンゲゼルシャフト	抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
ATE370961T1 (de)	1998-05-06	2007-09-15	Genentech Inc	Reinigung von antikörpern durch ionenaustauschchromatographie
ES2198922T3 (es)	1998-06-24	2004-02-01	Advanced Inhalation Research, Inc.	Particulas porosas grandes emitadas por un inhalador.
JP2002522063A (ja)	1998-08-17	2002-07-23	アブジェニックスインコーポレイテッド	増加した血清半減期を有する改変された分子の生成
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
ES2706547T3 (es)	1998-12-23	2019-03-29	Pfizer	Anticuerpos monoclonales humanos para CTLA-4
BR0009323A (pt)	1999-03-25	2002-01-08	Knoll Gmbh	Anticorpos humanos que ligam a il-12 humana e métodos para a produção
US6914128B1 (en) *	1999-03-25	2005-07-05	Abbott Gmbh & Co. Kg	Human antibodies that bind human IL-12 and methods for producing
EP2275540B1 (fr)	1999-04-09	2016-03-23	Kyowa Hakko Kirin Co., Ltd.	Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
EP2977063A1 (fr)	1999-06-25	2016-01-27	Genentech, Inc.	Procédés de traitement utilisant des conjugués maytansinoïdes-anticorps anti-ErbB
AU1456101A (en)	1999-11-03	2001-05-14	Maxygen, Inc.	Antibody diversity generation
SK12942002A3 (sk)	2000-02-10	2003-05-02	Abbott Laboratories	Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
HUP0300024A2 (en)	2000-02-24	2003-05-28	Genentech Inc	Caspase activated prodrugs therapy
YU63302A (sh)	2000-02-25	2005-09-19	The Government Of The Un.Stat.	Anti-egfrv iii scfvs sa pojačanom citotoksičnošću i povećanim prinosom, imunotoksini na bazi istog i metodi za upotrebu na bazi istog
EP1266014A2 (fr) *	2000-03-24	2002-12-18	Peter Kufer	Polypeptides multifonctionnnels comportant un site de fixation d'un du complexe recepteur nkg2d
PT2857516T (pt)	2000-04-11	2017-08-28	Genentech Inc	Anticorpos multivalentes e utilizações dos mesmos
EP1278778A2 (fr)	2000-05-03	2003-01-29	Amgen Inc.,	Peptides modifies comprenant un domaine fc utilises comme agents therapeutiques
CA2409361A1 (fr)	2000-05-19	2001-11-22	Scancell Limited	Anticorps humanises contre le recepteur du facteur de croissance epidermique
US7449308B2 (en)	2000-06-28	2008-11-11	Glycofi, Inc.	Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7029872B2 (en)	2000-06-28	2006-04-18	Glycofi, Inc	Methods for producing modified glycoproteins
PE20020132A1 (es)	2000-06-29	2002-03-04	Abbott Lab	Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
AU2001270609A1 (en)	2000-06-30	2002-01-14	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Heterodimeric fusion proteins
GB0020685D0 (en) *	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
US6699473B2 (en) *	2000-10-13	2004-03-02	Uab Research Foundation	Human anti-epidermal growth factor receptor single-chain antibodies
EP1345968A2 (fr)	2000-12-28	2003-09-24	Altus Biologics Inc.	Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees
NZ527302A (en)	2001-01-05	2006-10-27	Abgenix Inc	Antibodies to insulin-like growth factor I receptor
US7667004B2 (en) *	2001-04-17	2010-02-23	Abmaxis, Inc.	Humanized antibodies against vascular endothelial growth factor
US20100056762A1 (en) *	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
WO2002097048A2 (fr)	2001-05-30	2002-12-05	Centocor, Inc.	Proteines derivees de l'immunoglobuline anti-p40, compositions, procedes et utilisations
KR20100132559A (ko) *	2001-05-30	2010-12-17	제넨테크, 인크.	다양한 질환의 치료에 유용한 항-엔지에프 항체
KR100945108B1 (ko)	2001-06-13	2010-03-02	젠맵 에이/에스	표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
ATE524495T1 (de) *	2001-07-31	2011-09-15	Ono Pharmaceutical Co	Pd-1-spezifische substanz
WO2003016466A2 (fr)	2001-08-17	2003-02-27	Eli Lilly And Company	Anticorps anti-$g(a)$g(b)
US20030186374A1 (en)	2001-10-01	2003-10-02	Hufton Simon E.	Multi-chain eukaryotic display vectors and uses thereof
PL213948B1 (pl)	2001-10-25	2013-05-31	Genentech Inc	Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
WO2003039486A2 (fr)	2001-11-09	2003-05-15	Idec Pharmaceuticals Corporation	Anticorps anti-cd80 presentant une activite adcc visant la mort des cellules b de lymphome a mediation par adcc, isolement ou en combinaison avec d'autres therapies
BRPI0214168B8 (pt) *	2001-11-14	2021-05-25	Centocor Inc	anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
AU2002351353A1 (en) *	2001-12-19	2003-09-02	Genentech, Inc.	Stabilizing polypeptides which have been exposed to urea
EP1472275B1 (fr) *	2002-02-05	2008-12-17	Genentech, Inc.	Purification de proteines
MXPA04007583A (es)	2002-02-11	2005-04-25	Genentech Inc	Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno.
US7317091B2 (en) *	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US20040018573A1 (en)	2002-04-18	2004-01-29	Power Scott D	Production of functional antibodies in filamentous fungi
SI1501369T1 (sl)	2002-04-26	2015-10-30	Genentech, Inc.	Neafinitetno čiščenje proteinov
US20030206898A1 (en) *	2002-04-26	2003-11-06	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
EP1505075B1 (fr) *	2002-04-30	2009-10-07	Kyowa Hakko Kirin Co., Ltd.	Anticorps pour facteur de croissance humain semblable a l'insuline
MXPA04011624A (es)	2002-05-24	2005-03-07	Schering Corp	Anticuerpo neutralizante humano anti-igfr.
US9321832B2 (en) *	2002-06-28	2016-04-26	Domantis Limited	Ligand
EP1542724A4 (fr) *	2002-08-19	2005-10-19	Abgenix Inc	Anticorps diriges contre la proteine chimioattractive monocytaire 1 (mcp-1) et leurs utilisations
PT1543038T (pt)	2002-09-11	2017-07-07	Genentech Inc	Purificação de proteína
HUE035898T2 (en) *	2002-12-16	2018-05-28	Genentech Inc	Immunoglobulin variants and their applications
DK1575517T3 (da)	2002-12-24	2012-05-14	Rinat Neuroscience Corp	Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
WO2004065417A2 (fr) *	2003-01-23	2004-08-05	Genentech, Inc.	Procedes de production d'anticoprs humanises et d'amelioration du rendement d'anticorps ou de fragments de liaison d'antigenes en culture cellulaire
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP2330213A1 (fr)	2003-03-05	2011-06-08	Halozyme, Inc.	Glycoprotéine d'hyaluronidase soluble (sHASEGP), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant
EP2365001A3 (fr)	2003-05-01	2012-03-28	Imclone LLC	Anticorps humains dirigés contre le récepteur de facteur 1 de croissance de type insuline humaine
AU2004242846A1 (en) *	2003-05-31	2004-12-09	Micromet Ag	Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
EA015363B1 (ru)	2003-07-18	2011-06-30	Эмджен Инк.	Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
JP4599355B2 (ja) *	2003-07-28	2010-12-15	ジェネンテック，インコーポレイテッド	プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
US7662928B2 (en) *	2003-08-08	2010-02-16	The Research Foundation Of State University Of New York	Anti-FcRn antibodies for treatment of auto/allo immune conditions
US20050042664A1 (en)	2003-08-22	2005-02-24	Medimmune, Inc.	Humanization of antibodies
US20060134105A1 (en)	2004-10-21	2006-06-22	Xencor, Inc.	IgG immunoglobulin variants with optimized effector function
US7968684B2 (en)	2003-11-12	2011-06-28	Abbott Laboratories	IL-18 binding proteins
US7754500B2 (en) *	2003-11-21	2010-07-13	Anp Technologies, Inc.	Asymmetrically branched polymer conjugates and microarray assays
JP2007512846A (ja) *	2003-12-04	2007-05-24	ゼンコー・インコーポレイテッド	増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
US7794713B2 (en)	2004-04-07	2010-09-14	Lpath, Inc.	Compositions and methods for the treatment and prevention of hyperproliferative diseases
JP2007535317A (ja)	2004-04-15	2007-12-06	グライコフィ，インコーポレイテッド	下等真核生物におけるガラクトシル化された糖タンパク質の産生
EP1786918A4 (fr)	2004-07-17	2009-02-11	Imclone Systems Inc	Nouveau anticorps bispecifique tetravalent
ME01803B (fr) *	2004-08-05	2010-12-31	Genentech Inc	Antagonistes anti-cmet humanises
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
CA2577133A1 (fr)	2004-08-19	2006-03-23	Genentech, Inc.	Variants de polypeptides dotes d'une fonction effectrice modifiee
GB0419424D0 (en)	2004-09-02	2004-10-06	Viragen Scotland Ltd	Transgene optimisation
ES2377979T3 (es) *	2004-09-03	2012-04-03	Genentech, Inc.	Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
WO2006037604A1 (fr) *	2004-10-01	2006-04-13	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Nouveaux anticorps diriges contre la proteine de canal ionique eag1 mammifere
WO2006047350A2 (fr)	2004-10-21	2006-05-04	Xencor, Inc.	Variants d'immunoglobuline igg a fonction effectrice optimisee
US20060253100A1 (en) *	2004-10-22	2006-11-09	Medtronic, Inc.	Systems and Methods to Treat Pain Locally
US7423128B2 (en)	2004-11-03	2008-09-09	Amgen Fremont Inc.	Anti-properdin antibodies, and methods for making and using same
ZA200705695B (en) *	2004-12-21	2009-02-25	Astrazeneca Ab	Antibodies directed to angiopoietin-2 and uses thereof
EP2361933A3 (fr) *	2005-01-26	2012-05-02	Amgen Fremont Inc.	Anticorps contre l'interleukine-1 bêta
PT1853718E (pt) *	2005-02-15	2015-11-12	Univ Duke	Anticorpos anti-cd19 e usos em oncologia
NZ561763A (en)	2005-03-24	2009-02-28	Thrombogenics Nv	Novel anti PLGF antibody
CA2604032C (fr) *	2005-04-06	2017-08-22	Ibc Pharmaceuticals, Inc.	Methodes de generation de complexes lies stablement composes d'homodimeres, d'homotetrameres ou de dimeres de dimeres et utilisations associees
WO2006130374A2 (fr) *	2005-05-27	2006-12-07	Biogen Idec Ma Inc.	Anticorps se liant a tweak
ITRM20050290A1 (it) *	2005-06-07	2006-12-08	Lay Line Genomics Spa	Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko)	2005-08-19	2014-05-07	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
AU2006290433B2 (en) *	2005-08-26	2012-06-07	Roche Glycart Ag	Modified antigen binding molecules with altered cell signaling activity
US7906116B2 (en)	2005-09-01	2011-03-15	Parkash Gill	Methods for using and identifying modulators of Delta-like 4
CA2623648C (fr) *	2005-09-21	2018-05-22	The Regents Of The University Of California	Systemes, compositions et procedes pour representer localement et traiter la douleur
US8236308B2 (en)	2005-10-11	2012-08-07	Micromet Ag	Composition comprising cross-species-specific antibodies and uses thereof
EP1945771A1 (fr)	2005-10-28	2008-07-23	Novo Nordisk A/S	Protéines de fusion se liant aux lymphocytes effecteurs et aux cellules cibles
UA96139C2 (uk)	2005-11-08	2011-10-10	Дженентек, Інк.	Антитіло до нейропіліну-1 (nrp1)
PL1979001T3 (pl) *	2005-12-13	2012-09-28	Medimmune Ltd	Białka wiążące specyficzne dla insulinopodobnych czynników wzrostu i ich zastosowania
AR056857A1 (es)	2005-12-30	2007-10-24	U3 Pharma Ag	Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EA015992B1 (ru) *	2006-03-17	2012-01-30	Байоджен Айдек Эмэй Инк.	Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
MX2008011933A (es) *	2006-03-21	2008-12-18	Wyeth Corp	Metodos y composiciones para antagonismo de rage.
US20070232556A1 (en) *	2006-03-31	2007-10-04	Montine Thomas J	Methods and compositions for the treatment of neurological diseases and disorders
KR20110079922A (ko)	2006-04-14	2011-07-11	노파르티스 아게	안과 장애 치료를 위한 ｉｌ－1 항체의 용도
SMP200800064B (it)	2006-04-21	2009-11-06	Novartis Ag	Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
US20080118978A1 (en) *	2006-04-28	2008-05-22	Takashi Sato	Anti-tumor agent
CN101058609B (zh)	2006-05-26	2011-04-13	神州细胞工程有限公司	人源抗体及其表达
MX2008015138A (es) *	2006-06-02	2009-01-28	Aveo Pharmaceuticals Inc	Proteinas de union al factor de crecimiento de hepatocitos (fch).
JP2009539870A (ja) *	2006-06-06	2009-11-19	ジェネンテック・インコーポレーテッド	血管発生の調節ための組成物および方法
HRP20160082T1 (hr)	2006-09-29	2016-02-26	Oncomed Pharmaceuticals, Inc.	Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
CN106084055A (zh) *	2006-11-02	2016-11-09	健泰科生物技术公司	人源化的抗‑d因子抗体
EP2120996A2 (fr)	2006-12-20	2009-11-25	Vasgene Therapeutics, Inc.	Procédés d'utilisation et d'identification de modulateurs de dll4
WO2008100995A1 (fr) *	2007-02-14	2008-08-21	Vaccinex, Inc.	Anticorps humains anti-cd100
NZ579644A (en)	2007-02-16	2012-05-25	Merrimack Pharmaceuticals Inc	Antibodies against erbb3 and uses thereof
BRPI0809042B1 (pt) *	2007-03-22	2021-08-31	Biogen Ma Inc.	Proteína de ligação a cd154 isolada, seu uso, e composição
US20090068195A1 (en) *	2007-04-23	2009-03-12	Wyeth	Methods and compositions for treating and monitoring treatment of il-13-associated disorders
EP1997832A1 (fr)	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
US8227201B2 (en) *	2007-06-27	2012-07-24	Board Of Trustees Of The Leland Stanford Junior University	BETA2-microglobulin and C reactive protein (CRP) as biomarkers for peripheral artery disease
CN101952312A (zh) *	2007-07-31	2011-01-19	米迪缪尼有限公司	多特异性表位结合蛋白及其应用
EP2225268B1 (fr)	2007-10-19	2012-08-29	Abbott Laboratories	Dosages immunologiques et kits de détection de la ngal
US20100260668A1 (en)	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (fr)	2008-04-29	2012-04-25	Abbott Lab	Immunoglobulines à double domaine variable et utilisations
KR20110016959A (ko)	2008-06-03	2011-02-18	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
EP2297209A4 (fr)	2008-06-03	2012-08-01	Abbott Lab	Immunoglobulines à deux domaines variables et leurs utilisations
KR20110040886A (ko) *	2008-07-08	2011-04-20	아보트 러보러터리즈	프로스타글란딘 ｅ2 결합 단백질 및 이의 용도
US8822645B2 (en)	2008-07-08	2014-09-02	Abbvie Inc.	Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
SG171812A1 (en)	2008-12-04	2011-07-28	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
NZ594514A (en) *	2009-03-05	2013-06-28	Abbott Lab	Interleukin-17 BINDING PROTEINS
BRPI1012195A2 (en)	2009-05-01	2018-04-24	Abbott Laboratories	double variable domain immunoglobulins and their uses
WO2010127284A2 (fr) *	2009-05-01	2010-11-04	Abbott Laboratories	Immunoglobulines à deux domaines variables et ses utilisations
TW201109438A (en)	2009-07-29	2011-03-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
MX2012002651A (es) *	2009-09-01	2012-05-22	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
AU2010306681A1 (en) *	2009-10-15	2012-04-19	Abbvie Inc.	IL-1 binding proteins
AR078651A1 (es) *	2009-10-15	2011-11-23	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) *	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112012032778A2 (pt) *	2010-06-24	2019-09-24	Abbvie Inc	"proteínas multiespecíficas e multivalentes"
UY33492A (es) *	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130100118A (ko) *	2010-08-03	2013-09-09	아비에 인코포레이티드	이원 가변 도메인 면역글로불린 및 이의 용도
US9046513B2 (en) *	2010-08-26	2015-06-02	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
UY33707A (es) *	2010-11-04	2012-05-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas

2010
- 2010-09-01 MX MX2012002651A patent/MX2012002651A/es not_active Application Discontinuation
- 2010-09-01 US US12/873,926 patent/US8586714B2/en active Active
- 2010-09-01 IN IN2737DEN2012 patent/IN2012DN02737A/en unknown
- 2010-09-01 PE PE2012000278A patent/PE20121530A1/es not_active Application Discontinuation
- 2010-09-01 JP JP2012527113A patent/JP2013503607A/ja not_active Withdrawn
- 2010-09-01 NZ NZ598929A patent/NZ598929A/en not_active IP Right Cessation
- 2010-09-01 CN CN2010800491395A patent/CN102612524A/zh active Pending
- 2010-09-01 EP EP10814433.8A patent/EP2473524A4/fr not_active Withdrawn
- 2010-09-01 TW TW099129545A patent/TW201119673A/zh unknown
- 2010-09-01 WO PCT/US2010/047543 patent/WO2011028811A2/fr not_active Ceased
- 2010-09-01 AU AU2010289527A patent/AU2010289527C1/en not_active Ceased
- 2010-09-01 RU RU2012112550/10A patent/RU2012112550A/ru not_active Application Discontinuation
- 2010-09-01 SG SG2012014411A patent/SG178602A1/en unknown
- 2010-09-01 UY UY0001032870A patent/UY32870A/es not_active Application Discontinuation
- 2010-09-01 KR KR1020127008445A patent/KR20120060877A/ko not_active Withdrawn
- 2010-09-01 CA CA2772628A patent/CA2772628A1/fr not_active Abandoned
- 2010-09-01 AR ARP100103210A patent/AR078254A1/es not_active Application Discontinuation
- 2010-09-01 BR BR112012004710A patent/BR112012004710A2/pt not_active IP Right Cessation
2012
- 2012-02-29 IL IL218402A patent/IL218402A0/en unknown
- 2012-03-01 DO DO2012000055A patent/DOP2012000055A/es unknown
- 2012-03-01 CL CL2012000559A patent/CL2012000559A1/es unknown
- 2012-03-01 GT GT201200058A patent/GT201200058A/es unknown
- 2012-03-14 EC ECSP12011730 patent/ECSP12011730A/es unknown
- 2012-03-20 CO CO12047117A patent/CO6511254A2/es unknown
- 2012-03-27 CR CR20120154A patent/CR20120154A/es unknown
- 2012-03-28 ZA ZA2012/02268A patent/ZA201202268B/en unknown
2013
- 2013-10-17 US US14/056,116 patent/US20140134171A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2011028811A3 (fr)	2011-04-28
ZA201202268B (en)	2014-09-25
JP2013503607A (ja)	2013-02-04
IL218402A0 (en)	2012-04-30
NZ598929A (en)	2014-05-30
CO6511254A2 (es)	2012-08-31
PE20121530A1 (es)	2012-12-22
DOP2012000055A (es)	2012-07-31
BR112012004710A2 (pt)	2016-08-16
SG178602A1 (en)	2012-04-27
AU2010289527B2 (en)	2014-04-17
CL2012000559A1 (es)	2012-10-12
EP2473524A2 (fr)	2012-07-11
AU2010289527C1 (en)	2014-10-30
UY32870A (es)	2011-02-28
US8586714B2 (en)	2013-11-19
US20140134171A1 (en)	2014-05-15
CN102612524A (zh)	2012-07-25
MX2012002651A (es)	2012-05-22
KR20120060877A (ko)	2012-06-12
EP2473524A4 (fr)	2013-05-22
AR078254A1 (es)	2011-10-26
GT201200058A (es)	2014-01-28
AU2010289527A1 (en)	2012-04-19
CR20120154A (es)	2012-07-19
WO2011028811A2 (fr)	2011-03-10
CA2772628A1 (fr)	2011-03-10
RU2012112550A (ru)	2013-10-10
US20110091372A1 (en)	2011-04-21
TW201119673A (en)	2011-06-16
ECSP12011730A (es)	2012-04-30

Publication	Publication Date	Title
SG178602A1 (en)	2012-04-27	Dual variable domain immunoglobulins and uses thereof
PH12012500774A1 (en)	2012-11-26	Dual variable domain immunoglobulins and uses thereof
PH12012500815A1 (en)	2012-11-26	Dual variable domain immunoglobulins and uses thereof
MX2012004415A (es)	2012-05-08	Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012001262A (es)	2012-05-22	Inmunoglobulinas de dominio variable doble y usos de las misma.
MX2011011669A (es)	2011-11-18	Inmunoglobulinas de dominio variable dual y usos de las misma.
PH12012502523A1 (en)	2013-02-11	Dual variable domain immunoglobulins and uses thereof
PH12014500903A1 (en)	2014-06-09	Bispecific immunobinders directed against tnf and il-17
EP2373692A4 (fr)	2013-11-20	Immunoglobulines à double domaine variable et leurs utilisations
WO2012088290A3 (fr)	2012-09-07	Protéines de liaison à trois domaines variables et leurs utilisations
UA108198C2 (uk)	2015-04-10	Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MX2011011670A (es)	2011-11-18	Inmunoglobulinas de dominio variable dual y usos de las mismas.
PH12013500207A1 (en)	2017-08-23	Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en)	2017-08-23	Dual variable domain immunoglobulins and uses thereof
PH12013500867A1 (en)	2013-06-03	Dual variable domain immunoglobulins and uses thereof
PH12013501336A1 (en)	2013-08-28	Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
MX364200B (es)	2019-04-16	Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
EP2590671A4 (fr)	2013-12-18	Immunoglobulines à domaine variable double et leurs utilisations
MX2011007930A (es)	2011-09-06	Conjugados de insulina cristalina.
EA201001639A1 (ru)	2011-06-30	Композиции и способы их получения и применения
EA201190312A1 (ru)	2012-05-30	Замещенные пиперидины
EA201190313A1 (ru)	2012-05-30	Замещенные пиперидины
MX2015001648A (es)	2015-10-14	Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos.
TN2010000463A1 (en)	2012-05-24	Compositions and methods for preparing and using same
UA45312U (uk)	2009-11-10	Спосіб діагностики та лікування алергічних захворювань